Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.84 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12080351 | 0.99 | ADORA1 (0.82) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL1869039 | 0.91 | ADORA1 (1.00) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL18059615 | 0.90 | ADORA1 (0.84) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL12079015 | 0.90 | ADORA1 (1.00) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL1905912 | 0.88 | ADORA1 (0.69) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL1868527 | 0.88 | ADORA1 (0.80) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL6921191 | 0.87 | ADORA1 (0.80) | ADORA1ADORA2BADORA2AADORA3MEN1 | |
| SCHEMBL12092842 | 0.87 | ADORA1 (0.78) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL1866510 | 0.87 | ADORA1 (0.72) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL12089685 | 0.86 | ADORA1 (0.77) | ADORA1ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | claimed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | claimed |
| EP-2499142-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | Advinus Therapeutics Limited (IN) | 2012-09-19 | — | — | EP | claimed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | claimed |
| WO-2011055391-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-05-12 | — | — | WO | claimed |
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | disclosed |
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | disclosed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | disclosed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | disclosed |
| US-8796290-B2 | Substituted fused pyrimidine compounds, its preparation and uses thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-08-05 | — | — | US | disclosed |
| EP-2499142-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | Advinus Therapeutics Limited (IN) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-06 | — | — | US | disclosed |
| WO-2011055391-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225812-A1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADORA1, ADORA2A, P2RY1 | ADORA1 1/4885ADORA2B 12/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.